Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
Myriad Genetics has expanded retail access to SneakPeek, the first at-home early fetal sex DNA test, making it available in over 8,800 retail locations nationwide, including Walmart, Walgreens, and CVS stores. The test, which offers over 99% accuracy as early as six weeks into pregnancy, uses a patented SneakPeek Snap device for blood sample collection. According to a 2024 consumer survey, 82% of expectant parents want to know their baby's sex before delivery, with a majority preferring in-store purchases over online ordering. The retail launch precedes a 2025 product rebrand featuring new packaging and website design focused on gender discovery as a key moment of parental bonding.
Myriad Genetics ha ampliato l'accesso al pubblico al SneakPeek, il primo test DNA per determinare il sesso del feto da casa, rendendolo disponibile in oltre 8.800 punti vendita a livello nazionale, inclusi Walmart, Walgreens e CVS. Il test, che offre un'accuratezza superiore al 99% già a partire dalla sesta settimana di gravidanza, utilizza un dispositivo brevettato SneakPeek Snap per la raccolta del campione di sangue. Secondo un sondaggio sui consumatori del 2024, l'82% dei genitori in attesa desidera conoscere il sesso del proprio bambino prima della nascita, con la maggior parte che preferisce gli acquisti in negozio rispetto agli ordini online. Il lancio al dettaglio precede un rebranding del prodotto previsto per il 2025, che presenterà un nuovo packaging e un design del sito web focalizzato sulla scoperta del genere come un momento chiave per il legame genitore-figlio.
Myriad Genetics ha ampliado el acceso al público para SneakPeek, la primera prueba de ADN para determinar el sexo fetal en casa, haciéndola disponible en más de 8,800 tiendas en todo el país, incluyendo Walmart, Walgreens y CVS. La prueba, que ofrece más del 99% de precisión desde la sexta semana de embarazo, utiliza un dispositivo patentado SneakPeek Snap para la recolección de muestras de sangre. Según una encuesta de consumidores de 2024, el 82% de los padres expectantes quieren saber el sexo de su bebé antes del parto, siendo la mayoría de ellos favorables a las compras en tienda en lugar de pedir en línea. El lanzamiento al por menor precede a un rebranding del producto en 2025 que incluirá un nuevo empaque y un diseño de sitio web enfocado en el descubrimiento de género como un momento clave para el vínculo parental.
Myriad Genetics는 SneakPeek의 소매 접근성을 확대하여 이 가정용 조기 태아 성별 DNA 테스트를 전국 8,800개 이상의 소매점에서 제공하게 되었습니다. 여기에는 Walmart, Walgreens 및 CVS 매장이 포함됩니다. 이 테스트는 임신 6주 차부터 99% 이상의 정확성을 제공하며, 혈액 샘플 수집을 위해 특허받은 SneakPeek Snap 장치를 사용합니다. 2024년 소비자 설문 조사에 따르면, 82%의 예비 부모가 출산 전에 아기의 성별을 알고 싶어하며, 대부분이 온라인 주문보다 매장에서 구매하는 것을 선호한다고 합니다. 소매 출시 이전에 2025년에는 성별 발견을 부모 간의 유대의 중요한 순간으로 강조한 새로운 포장 및 웹사이트 디자인을 특징으로 하는 제품 리브랜딩이 진행될 예정입니다.
Myriad Genetics a élargi l'accès au détail à SneakPeek, le premier test ADN à domicile pour déterminer le sexe du fœtus, le rendant disponible dans plus de 8 800 points de vente à travers le pays, y compris Walmart, Walgreens et CVS. Le test, qui offre une précision de plus de 99% dès la sixième semaine de grossesse, utilise un dispositif breveté SneakPeek Snap pour la collecte d'échantillons de sang. Selon une enquête menée en 2024, 82% des futurs parents souhaitent connaître le sexe de leur bébé avant l'accouchement, la majorité préférant faire leurs achats en magasin plutôt qu'en ligne. Le lancement au détail précède un rebranding du produit prévu pour 2025, comprenant un nouvel emballage et un design de site web axé sur la découverte du genre comme un moment clé de liaison parentale.
Myriad Genetics hat den Einzelhandelszugang zu SneakPeek, dem ersten DNA-Test zur frühen Bestimmung des Geschlechts des Fötus, der zu Hause durchgeführt werden kann, erweitert und macht ihn in über 8.800 Einzelhandelsstandorten landesweit verfügbar, einschließlich Walmart, Walgreens und CVS. Der Test, der eine Genauigkeit von über 99% bereits ab der sechsten Schwangerschaftswoche bietet, verwendet ein patentiertes SneakPeek Snap-Gerät zur Blutprobenentnahme. Laut einer Verbraucherumfrage aus dem Jahr 2024 möchten 82% der werdenden Eltern das Geschlecht ihres Babys vor der Geburt erfahren, wobei die Mehrheit in Geschäften einkaufen und nicht online bestellen möchte. Der Einzelhandelsstart geht einem Rebranding des Produkts im Jahr 2025 voraus, das eine neue Verpackung und ein Webdesign umfasst, das sich auf die Geschlechtsentdeckung als einen wichtigen Moment der Elternbindung konzentriert.
- Significant retail expansion to 8,800+ locations including major chains
- Strong market demand confirmed by 82% of expectant parents wanting early gender testing
- High accuracy rate of over 99% for the test
- First-to-market advantage as the only 6-week early detection test available in retail
- None.
Insights
The retail expansion of SneakPeek into 8,800+ locations represents a significant market opportunity for Myriad Genetics. With
The timing of this expansion, coupled with the planned 2025 rebranding initiative, positions MYGN to capture a larger share of the prenatal testing market. The
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide
SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over
According to a 2024 consumer survey,
“Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it,” said Melissa Gonzales, president of women’s health, Myriad Genetics. “By expanding access of the SneakPeek test through national retail partners, we’re making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood.”
The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand’s new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby’s gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over
Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor’s offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek’s parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.
How the Test Works
The retail test kit includes the patented SneakPeek Snap® device, which is placed on the user’s upper arm to nearly painlessly collect a blood sample with the simple press of a button. The sample is then mailed to the SneakPeek laboratory in the included, postage-paid envelope. Test results are delivered as early as the same day the sample is received through a celebratory text message and email.
The SneakPeek test is now available in Walmart, Walgreens and CVS stores. Click here to find a store near you.
About SneakPeek
Through the SneakPeek test, Myriad Genetics is on a mission to make DNA-based prenatal information affordable and accessible for all families. For more information, visit sneakpeektest.com and follow the brand on Instagram and Facebook.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company expects that SneakPeek’s expansion into retailers in the United States will improve the products affordability and accessibility so that the test may be available to many more families who want to learn the sex of their baby at-home as early as six weeks into pregnancy and that a product rebrand, new packaging design, and a website centered on the moment of gender discovery are scheduled for launch in 2025. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
[1] In a 2021 laboratory test, SneakPeek accurately determined fetal sex in
[2] Gateway Genomics Research, August 2022; n=200.
[3] January 2024 Padilla Newsmaker Online Survey of 1,000 women age 21-45 who are trying to conceive, pregnant or have been pregnant.
FAQ
Where can I buy the SneakPeek fetal sex test from Myriad Genetics (MYGN)?
How accurate is Myriad Genetics' (MYGN) SneakPeek gender test?
When will Myriad Genetics (MYGN) launch the new SneakPeek branding?
How does the SneakPeek test from Myriad Genetics (MYGN) work?
